administered at 0.5 mg/ml. Figure S2 . (A) Schematic illustrating design of pilot study to test toxicity of selected drugs delivered by topical administration. Shaved exposed skin is tape-stripped prior to topical delivery of sterile drug solutions (0.5, 2 and 10 mg/ml, n=4 mice/dose) on a patch of sterile gauze secured with bio-occlusive dressing. Inflammation is visually assessed following 1 week. (B) Summary of drug toxicity (as assessed by visual inspection of skin for edema) at 0.5, 2 and 10 mg/ml doses. The toxicity of drugs is presented as a greyscale with lighter shades representing less/or no edema, and darker shades more severe edema.
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Topical administration of repositioned drug set has no significant effect on body weight, relative to PBS controls. Figure S3 . Bodyweights of mice during pilot study to help assess toxicity of repositioned drug set following topically delivery (at 0.5, 2 and 10 mg/ml doses). Weights are Table S1 . Statistical analysis of inflammatory parameters examined in ovalbumin-mediated epicutaneous sensitization model of AD following treatment with the repositioned drug set using the Post hoc Dunnet-t test, relative to PBS control treatment (p-values<0.05 are highlighted in red).
* Asterisk marks a significant increase in an inflammation parameter, relative to PBS controls. 
